Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cell division cycle protein 23 homolog (CDC23) is an essential subunit of the anaphase-promoting complex/cyclosome (APC/C), a large, multisubunit E3 ubiquitin ligase that controls progression through mitosis and G1 phase by catalyzing ubiquitin-mediated degradation of key regulators such as cyclin B1 and securin[2][3][4]. It contains tetratricopeptide repeat (TPR) domains important for protein–protein interactions within the complex. CDC23 is critical for orderly cell cycle transition, and its dysfunction causes cell cycle arrest, inhibits proliferation, and is linked to several cancers[1][3][4]. Recent studies indicate CDC23 may contribute to tumorigenesis and metastasis by regulating the epithelial-mesenchymal transition (EMT), and its expression is significantly higher in various cancer cell types, making it a potential novel therapeutic target[1][3][4].
Inhibition or knockdown causes arrest in G2/M phase by blocking ubiquitin-mediated degradation of key cell cycle regulators (e.g., cyclin B1, securin)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell division cycle protein 23 homolog (CDC23).